A Preclinical Study to Investigate the Development of Nephrogenic Systemic Fibrosis: A Possible Role for Gadolinium-Based Contrast Media
暂无分享,去创建一个
T. Frenzel | H. Weinmann | H. Pietsch | M. Sieber | J. Walter | W. Haider
[1] Raimund Erbel,et al. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. , 2009, Journal of the American College of Cardiology.
[2] B. Watschinger,et al. Sympathische Überaktivität und Niere , 2003, Wiener Klinische Wochenschrift.
[3] W. Haschek,et al. Skin and Oral Mucosa , 2009 .
[4] G. Saab,et al. Are patients with moderate renal failure at risk for developing nephrogenic systemic fibrosis? , 2007, Radiology.
[5] M. Tweedle. "Stability" of gadolinium chelates. , 2007, The British journal of radiology.
[6] H. Schmitt-Willich. Stability of linear and macrocyclic gadolinium based contrast agents. , 2007, The British journal of radiology.
[7] A. Djamali,et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. , 2007, Radiology.
[8] E. Kanal,et al. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. , 2007, Radiology.
[9] V. Runge,et al. Nephrogenic Systemic Fibrosis: A Review of 6 Cases Temporally Related to Gadodiamide Injection (Omniscan) , 2007, Investigative radiology.
[10] P. Champéroux,et al. Cardiovascular Safety of Gadoterate Meglumine (Gd-DOTA) , 2007, Investigative radiology.
[11] Gerhard Adam,et al. Clinical Safety and Diagnostic Value of the Gadolinium Chelate Gadoterate Meglumine (Gd-DOTA) , 2007, Investigative radiology.
[12] S. Jimenez,et al. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: clinical aspects. , 2007, Skinmed.
[13] M. Port,et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review , 2006, Fundamental & clinical pharmacology.
[14] J. Finsterer,et al. Dermal and extra-dermal manifestations of gadolinium-triggered nephrogenic fibrosing dermopathy. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[15] Kevan G. Lewis,et al. Nephrogenic fibrosing dermopathy and calciphylaxis with pseudoxanthoma elasticum‐like changes , 2006, Journal of cutaneous pathology.
[16] Lone Skov,et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.
[17] M. Knopp,et al. Assessment of Utilization and Pharmacovigilance Based on Spontaneous Adverse Event Reporting of Gadopentetate Dimeglumine as a Magnetic Resonance Contrast Agent After 45 Million Administrations and 15 Years of Clinical Use , 2006, Investigative radiology.
[18] S. Cowper,et al. Editorials: Nephrogenic Systemic Fibrosis: An Emerging Threat Among Renal Patients , 2006, Seminars in dialysis.
[19] T. Grobner. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[20] T. Ishiguchi,et al. Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. , 2005, Radiation medicine.
[21] R. Elenitsas,et al. Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema , 2005, Journal of cutaneous pathology.
[22] J. Yamate,et al. Effects of gadolinium chloride (GdCl(3)) on the appearance of macrophage populations and fibrogenesis in thioacetamide-induced rat hepatic lesions. , 2005, Journal of comparative pathology.
[23] Susanne A. Fischer,et al. In Vitro Cultivation of an Insect Microsporidian Tubulinosema ratisbonensis in Mammalian Cells , 2005, The Journal of eukaryotic microbiology.
[24] S. Jimenez,et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. , 2004, Arthritis and rheumatism.
[25] D. Lipsker,et al. Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis , 2004, The British journal of dermatology.
[26] Shawn Cowper,et al. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. , 2004, The international journal of biochemistry & cell biology.
[27] J. English,et al. Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy , 2004, Journal of cutaneous pathology.
[28] Dawn G Goodman,et al. Best Practices Guideline: Toxicologic Histopathology , 2004, Toxicologic pathology.
[29] S. Cowper. Nephrogenic fibrosing dermopathy: the first 6 years , 2003, Current opinion in rheumatology.
[30] W. Shoji,et al. Reduction of recipient macrophages by gadolinium chloride prevents development of obliterative airway disease in a rat model of heterotopic tracheal transplantation , 2003, Transplantation.
[31] A. Habicht,et al. [Sympathetic overactivity and the kidney]. , 2003, Wiener klinische Wochenschrift.
[32] R. Bucala,et al. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. , 2003, The American Journal of dermatopathology.
[33] P. Leboit,et al. Nephrogenic Fibrosing Dermopathy , 2001, The American Journal of dermatopathology.
[34] E.,et al. Paramagnetic Metal Complexes as Water Proton Relaxation Agents for NMR Imaging : Theory and Design , 2001 .
[35] P. Leboit,et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.
[36] E. Brücher,et al. The rates of the exchange reactions between [Gd(DTPA)]2- and the endogenous ions Cu2+ and Zn2+: a kinetic model for the prediction of the in vivo stability of [Gd(DTPA)]2-, used as a contrast agent in magnetic resonance imaging. , 2000, Chemistry.
[37] R. Lauffer,et al. Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.
[38] H. Thomsen,et al. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. , 1998, Academic radiology.
[39] A. Reid,et al. Gadolinium Chloride Toxicity in the Rat , 1997, Toxicologic pathology.
[40] W. Gibby,et al. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. , 1996, Investigative radiology.
[41] W. Gibby,et al. Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media. , 1996, Investigative radiology.
[42] P. Wedeking,et al. Biodistribution of Radiolabeled, Formulated Gadopentetate, Gadoteridol, Gadoterate, and Gadodiamide in Mice and Rats , 1995, Investigative radiology.
[43] H. Weinmann,et al. Pharmacokinetics, Dose Proportionality, and Tolerability of Gadobutrol after Single Intravenous Injection in Healthy Volunteers , 1994, Investigative radiology.
[44] E. Holtz,et al. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. , 1993, Investigative radiology.
[45] P. Wedeking,et al. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. , 1992, Magnetic resonance imaging.
[46] G. Krestin,et al. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. , 1991, Investigative radiology.
[47] S. Quay,et al. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. , 1991, Investigative radiology.
[48] J. Hagan,et al. Reaction of gadolinium chelates with endogenously available ions. , 1991, Magnetic resonance imaging.
[49] W. Cacheris,et al. The relationship between thermodynamics and the toxicity of gadolinium complexes. , 1990, Magnetic resonance imaging.
[50] G. Krinke,et al. Pyridoxine Megavitaminosis: An Analysis of the Early Changes Induced with Massive Doses of Vitamin B6 in Rat Primary Sensory Neurons , 1985, Journal of neuropathology and experimental neurology.
[51] R. Brasch,et al. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. , 1984, AJR. American journal of roentgenology.
[52] H. Weinmann,et al. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. , 1984, Physiological chemistry and physics and medical NMR.